XNAS
DRMA
Market cap4mUSD
Jun 24, Last price
0.63USD
1D
-0.32%
1Q
-53.33%
IPO
-99.25%
Name
Dermata Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.06%
Rev. gr., 5y
%
Revenues
0k
Net income
-12.29b
L+157,538.87%
CFO
-11.16b
L+174,078.00%
Profile
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 12,513,242 | 8,042 | 9,674 | |||
Unusual Expense (Income) | ||||||
NOPBT | (12,513,242) | (8,042) | (9,674) | |||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | (12,513,242) | (8,042) | (9,674) | |||
Net income | (12,287,461) 157,538.87% | (7,795) -18.90% | (9,611) 20.92% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 6,885 | 7,606 | 4,277 | |||
BB yield | -333.40% | -6,395.25% | -94.62% | |||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | 1,164,783 | 497 | ||||
Net debt | (3,161,570) | (7,438) | (6,241) | |||
| Cash flow | ||||||
Cash from operating activities | (11,162,948) | (6,409) | (8,834) | |||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | 6,886 | 7,606 | 4,277 | |||
FCF | (12,513,242) | (8,042) | (9,674) | |||
| Balance | ||||||
Cash | 3,161,570 | 7,438 | 6,241 | |||
Long term investments | ||||||
Excess cash | 3,161,570 | 7,438 | 6,241 | |||
Stockholders' equity | (65,675,339) | (53,387) | (45,592) | |||
Invested Capital | 69,207,254 | 59,743 | 51,614 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 1,530 | 195 | 691 | |||
Price | 1.35 121.31% | 0.61 -90.68% | 6.54 -76.49% | |||
Market cap | 2,065 1,636.54% | 119 -97.37% | 4,520 -68.81% | |||
EV | (3,159,505) | (7,319) | (1,722) | |||
EBITDA | (12,513,242) | (8,042) | (9,674) | |||
EV/EBITDA | 0.25 | 0.91 | 0.18 | |||
Interest | 64 | |||||
Interest/NOPBT | ||||||